Gene Therapy for Mitochondrial Diseases: Current Status and Future Perspective.

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Biochemistry

Background:

• Mitochondrial diseases (MDs) are severe genetic disorders stemming from mutations affecting the oxidative phosphorylation (OXPHOS) system.
• These conditions present diverse symptoms, from organ-specific to multisystemic, with varied clinical outcomes.
• Therapeutic development for MDs is hindered by limited natural history data, inadequate preclinical models, and broad phenotypic variability.

Purpose of the Study:

• To provide a comprehensive overview of the current status of gene therapy for mitochondrial diseases.
• To identify and discuss the primary challenges impeding gene therapy progress in MDs.
• To explore potential solutions and future directions for gene therapy in the field of MDs.

Main Methods:

• Review of current pre-clinical and clinical trials in gene therapy for MDs.
• Analysis of obstacles including vector design, tissue tropism, delivery efficiency, transgene expression, and immunotoxicity.
• Synthesis of existing literature to outline the state-of-the-art in MD gene therapy.

Main Results:

• Gene therapy has emerged as a viable precision medicine strategy for MDs.
• Significant hurdles remain, including optimizing vector technology and ensuring safe, effective delivery.
• Progress in clinical trials indicates the potential of gene therapy for treating these complex genetic disorders.

Conclusions:

• Gene therapy holds considerable promise for treating mitochondrial diseases.
• Addressing challenges in vector development, delivery, and immunogenicity is crucial for successful clinical translation.
• Continued research and innovation are essential to realize the full potential of gene therapy for MDs.